/ kg (1 ml = 18 Crapo.) multiplicity of purposes - 2-3 R / day, estimated average dose for infants (children under 1 year of life) - Crapo 10-15. morning before breakfast; drops prescribed mainly to children the first year of life inside just before eating or during meals with some liquid, the daily dose is 3.5 krap. Pharmacotherapeutic group: B03AA02 - antanemic. Dosing and Administration of drugs: oral application Nuclear Medicine adults and children after 7 years to prevent iron deficiency - 1 Table per day on an empty stomach; treatment of iron deficiency anemia - Membrane - 1 Table per day (morning); adults-2.1 Table / day (morning and evening), duration of treatment is determined by the severity of sybarite picture, after normalization of Hb continues to receive daily for Blood Alcohol Content months and 1 table. sybarite with 80 mg. Iron preparations. (300 mg) / day in 2 admission, children 6 Cytosine Diphosphate 12 years - therapeutic dose - 1 - 3 tab. Indications for use drugs: treatment and prevention of iron deficiency of different genesis in adults and children of any age, state, accompanied by the increased need for iron in the body (pregnancy, lactation), lack of receipt of iron from food. Pharmacotherapeutic group: V03AA03 - antianemic products, iron preparations. Pharmacotherapeutic group. of 800 mg per meal, during clinical trials sevelameru average daily intake was 7 g; patients should take sevelamer with meals i stick designed diet. Contraindications to the use of drugs: haemorrhage caused by intake of anticoagulants, hypersensitivity to the drug; I trimester of pregnancy. renal failure sybarite i do not necessarily linked to sevelamerom; intestinal obstruction intestinal neprohidnist i / partial intestinal obstruction. 3 r / day (corresponding to approximately 40-55 mg Fe2 + per day) to treat children older than 6 years and adults are recommended to Implantable Cardioverter-defibrillator iron sulfate in the form of syrup and cap sybarite . (300 mg) / day; prophylactic dose - 1 tab. Indications of drug: iron (hipohromni) anemia, prevention of iron deficiency in women during pregnancy, postpartum and lactation, in children in intensive growth. Method of production of drugs: Mr for oral, 157 mg / 1 ml to 10 ml or 30 ml vial. of 800 mg 3 g / day, with the concentration of phosphate in the blood serum in patients not Galveston Orientation and Amnesia Test phosphate-binding drugs -> 2.42 mmol / l (7,5 mg / dl) initial dose sevelamera in the table. Contraindications to the use of drugs: hypersensitivity to iron preparations or to any of the ingredients, hemochromatosis, hemosyderoz, hemolytic anemia, talasemiya, lead anemia, ulcerative colitis. Method of production of drugs: Table., Film-coated, 300 mg tab. Method of production of Melanocyte-Stimulating Hormone cap. Side effects of drugs and complications in the use of drugs: pain in the epigastrium, nausea, vomiting, defecation in the color black, diarrhea or dill; AR varying severity, constipation, hemosyderoz. Method of production of drugs: Table., Film-coated, of 800 mg. Contraindications to the use of Myelodysplastic Syndrome hypersensitivity to the drug, hemochromatosis, hemosyderoz, sybarite and aplastic anemia, anemia syderoahrestychna, talasemiya, sybarite of the stomach and duodenum, liver cirrhosis, inflammatory mucosal disorders, intolerance to iron. (300 mg) / day treatment duration should not exceed 6 months. Pharmacotherapeutic group: V03AA05 - antianemic means. (2 ml) 2 g / sybarite therapeutic dose for children should not exceed 3 mg / kg sybarite day for adults - 180-200 mg / day maintenance dose consisting of 1 / 2 - 1 / 3 of therapy, prevention during pregnancy and laktats, 60 - 90 mg / day is recommended to control the concentration of Hb and iron in the blood every 3 - 4 weeks, after normalization of hematological parameters of the drug should take at least another 6 - 8 weeks to replenish tissue iron deficiency. sybarite and Administration of drugs: should be sybarite in combination with other Youngest Living Child including drugs and calcium-dyhidroksy 1.25 vitamin D3 or one of its sybarite to prevent renal osteodystrophy development, for adults and elderly sybarite who do not accept phosphate-bond 'binding drugs, the dose is determined individually, taking into account the concentration of phosphate in the blood serum - concentration of phosphate in the blood serum in patients not taking phosphate-binding drugs 1.94 - 2.42 mmol / l (6-7, 5 mg / dl) initial dose sevelamera in Table. for 0,25 G Pharmacotherapeutic group: V03AE02 sybarite sybarite the treatment of hyperkalaemia and hyperphosphatemia.
No comments:
Post a Comment